assignment
Recruiting

Evaluation of Fixed-Duration Ibrutinib and Obinutuzumab Therapy in Treatment-Naïve Chronic Lymphocytic Leukemia Patients

Trial ID
2024-514824-18-00

Register record, history and transparency: CTIS.eu

Trial statistics

science
2
test molecules
location_city
6
research sites
public
1
country
medical_information
2
diseases
person_search
6
investigators

Diseases & Conditions

Chronic lymphocytic leukaemiaB-cell small lymphocytic lymphoma

Objectives

The primary objective of this study is to evaluate the percentage of **bone marrow minimal residual disease** (BM MRD) at a level of less than 10-4 in bone marrow at 30 days of follow-up after treatment with **ibrutinib** and **obinutuzumab** in patients with **chronic lymphocytic leukemia** (CLL). This objective is clinically relevant as achieving a low level of MRD is associated with improved long-term outcomes and progression-free survival in CLL patients. The study focuses on treatment-naïve patients, providing insights into the efficacy of this combination therapy as a first-line treatment option.

Participants

The clinical trial involves participants diagnosed with **chronic lymphocytic leukemia** or small lymphocytic lymphoma, as per iwCLL diagnostic criteria. The study population includes both male and female subjects aged 18 years and older. Participants are required to have previously untreated active disease necessitating treatment according to iwCLL criteria, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. The trial does not specify the total number of participants, as this information was not provided by the sponsor. The selection criteria include adequate blood count, liver, and kidney function, as well as measurable lymph node disease. The trial population is inclusive of a vulnerable population, although specific lifestyle considerations such as diet or physical activity are not detailed. Key inclusion criteria emphasize the necessity for participants to have adequate organ function and measurable disease, while exclusion criteria are not explicitly mentioned.

Plans and Procedures

The clinical trial is designed to evaluate the efficacy of a fixed-duration therapy using **ibrutinib** and **obinutuzumab** in treatment-naïve patients diagnosed with **chronic lymphocytic leukemia** (CLL) or small lymphocytic lymphoma (SLL). This study is a Phase II, randomized, double-blind, controlled trial. The trial is expected to last until March 31, 2027, with recruitment having commenced on March 31, 2021. Participants will be involved in the study for a maximum treatment period of 24 months.

The trial involves a sequence of study visits, beginning with an inclusion (screening) visit to confirm eligibility based on criteria such as age (≥18 years), diagnosis according to iwCLL criteria, and adequate organ function. Following the screening, participants will undergo treatment cycles with ibrutinib administered orally and obinutuzumab administered intravenously. Ibrutinib will be given in cycles 1-24, while obinutuzumab will be administered during cycle 13 on days 1, 2, 8, and 15, and on day 1 of cycles 14-18. The primary endpoint is the percentage of patients achieving minimal residual disease (MRD) levels of less than 10^-4 in bone marrow at 30 days post-therapy completion.

Follow-up visits will be conducted to monitor the participants' response to treatment and any adverse effects. The end-of-study visit will assess the final outcomes and collect data on the primary endpoint. Participants may be withdrawn from the study early if they experience significant adverse events, fail to comply with the study protocol, or withdraw consent. The trial aims to provide valuable insights into the effectiveness of this treatment regimen in achieving MRD negativity in CLL/SLL patients.

Treatment

The clinical trial involves the administration of **Obinutuzumab**, a monoclonal antibody classified under the ATC code L01XC15. The pharmaceutical form of Obinutuzumab is denoted as PHF00230MIG. It is administered via **intravenous use**. The maximum daily and total dose of Obinutuzumab is 1000 mg, with a treatment period extending up to 24 months. The dosing schedule for Obinutuzumab includes administration on Cycle 13 Days 1, 2, 8, and 15, and on Day 1 of Cycles 14 through 18. Obinutuzumab is designated as an orphan drug under the number EU/3/12/1054.

**Ibrutinib** is the second experimental medication used in this trial, classified under the ATC code L01XE27. The pharmaceutical form of Ibrutinib is PHF00082MIG, and it is administered **orally**. The maximum daily and total dose for Ibrutinib is 420 mg, with a treatment period also extending up to 24 months. Ibrutinib is a chemical substance, and its administration is continuous throughout Cycles 1 to 24. The chemical name for Ibrutinib is 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.

Participant compliance with the dosing schedule will be monitored throughout the trial. No non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatments, are specified in this study. The trial aims to evaluate the percentage of bone marrow minimal residual disease (BM MRD) less than 10^-4 at 30 days of follow-up after the administration of Ibrutinib and Obinutuzumab.

Efficacy

Efficacy in this clinical trial will be assessed by evaluating the primary endpoint, which is the percentage of patients achieving **minimal residual disease (MRD)** levels of less than 10-4 in the bone marrow (BM) at 30 days following the completion of therapy. This endpoint will be measured after the administration of ibrutinib over cycles 1 to 24 and obinutuzumab during cycle 13 on days 1, 2, 8, and 15, and cycles 14 to 18 on day 1. The assessment of MRD will be conducted using validated laboratory tests to ensure accuracy and reliability of the results. The trial is designed to provide a fixed-duration therapy for treatment-naïve patients with chronic lymphocytic leukemia (CLL) or small lymphocyte lymphoma (SLL), with the aim of determining the efficacy of the combination of ibrutinib and obinutuzumab in achieving deep remission as indicated by MRD levels.

Inclusion and Exclusion Criteria

check_circle

Inclusion Criteria

  • Age >=18 years
  • Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocyte lymphoma (SLL) according to iwCLL diagnostic criteria
  • Previously untreated active disease requiring treatment according to iwCLL criteria
  • ECOG PS 0 or 1
  • Lymph node disease measurable (longest diameter> 1.5 cm) by CT
  • Adequate blood count defined as: Absolute neutrophil count (ANC)> 750 cells / μL (750 cells / mm3 or 0.75 x 109 / L), Platelet count> 30,000 / μL (30,000 cells / mm3 or 30 x 109 / L), Hemoglobin> 8.0 g / dL
  • Adequate liver and kidney function defined as: Serum aspartate transaminase (AST) or alanine transaminase (ALT) =3.0 x upper limit of normal (ULN) , Estimated Creatinine Clearance (CrCl) =30 mL / min (Cockcroft-Gault), Bilirubin =1.5 x ULN (unless increased bilirubin is due to Gilbert's syndrome or of non-hepatic origin)
  • Prothrombin time (PT) / International normal ratio (INR) <1.5 x ULN and PTT (activated partial thromboplastin time [aPTT]) <1.5 x ULN (unless abnormalities are related to coagulopathy or bleeding disorder)
cancel

Exclusion Criteria

  • Any prior therapy (including but not limited to chemotherapy, targeted therapy, immunomodulatory therapy, radiotherapy, and / or monoclonal antibody) used to treat CLL or SLL.
  • Patients with del (17p) and / or TP53 mutation according to centralized laboratory assessment.
  • History of other malignancies, except: Malignant tumor treated with curative intent and with no known active disease present for =3 prior to first dose of study drug and deemed low risk of recurrence by treating physician, Malignant skin neoplasm not adequately treated or lentigo maligna with no evidence of disease, Adequately treated carcinoma in situ with no evidence of disease.
  • Known or suspected history of Richter's transformation.
  • Known hypersensitivity to one or more study drugs.
  • Known bleeding disorders (eg von Willebrand disease or haemophilia).
  • History of stroke or intracranial haemorrhage within 6 months prior to enrollment.
  • Known history of human immunodeficiency virus (HIV) or active hepatitis C virus (HCV) or hepatitis B virus (HBV) infection. Individuals who are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) result before enrollment. Those who test positive for PCR will be excluded.
  • Inability to swallow capsules / tablets or malabsorption syndrome, any disease that significantly affects gastrointestinal function, or resection of the stomach or small intestine, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction.
  • Concomitant use of warfarin or other vitamin K antagonists.
  • Major surgery within 4 weeks of the first dose of study drug

Trial Status by Country

Country Status Start of Recruitment Planned Patients
Italy ItalyRecruiting31 Mar 202153

Sites & Investigators

Investigational Products

Details about the medicinal products being studied in this clinical trial.

Product Name Role in Trial Formulation Administration Max Daily Dose Treatment Duration EU MP Number
OBINUTUZUMAB
TestPHF00230MIGINTRAVENOUS USE100024SCP276011
IBRUTINIB
TestPHF00082MIGORAL USE42024SCP31316411

Conditions Studied in This Trial

Interventions Studied in This Trial

vaccines
Ibrutinib
45 trials

Also investigated for

Chronic lymphocytic leukaemia 19B-cell small lymphocytic lymphoma 10Mantle cell lymphoma 10Waldenstrom's macroglobulinaemia 5